Abstract Recent studies have established a relation be tween elevated alanine aminotransferase levels In donor (jjood and the incidence of non-A,non-B hepatitis in reciplmis of such blood. Routine testing of donor blood for ala ni ne aminotransferase activity in order to reduce hepatitis is not currently supported, largely because the results of such testing are unknown. We assessed the potential economic benefits of screen ing donor Wood for alanine aminotransferase as a means t o reduce post-transfusion hepatitis. Benefits, defined as the expected costs of hepatitis potentially avoided, ranged Irom $898 to $31,629 per 1000 blood units collected. This wi de range reflected lack of information about the natural history of non-A,non-B hepatitis.
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W E undertook a collaborative study to estimate the potential costs" and benefits to society of implementing a national program to screen donor blood for elevated levels of serum alanine aminotrans ferase (ALT). Two other recent studies, the Transfu sion-Transmitted Viruses Study' and a study by the National Institutes of Health, 2 showed an association between the transfusion of donor blood with elevated ALT levels and post-transfusion ALT elevations in recipients of such blood units. In both studies, these signs of liver dysfunction in recipients were defined as post-transfusion non-A,non-B hepatitis. The results of these studies have been interpreted as evidence that the incidence of post-transfusion hepatitis could be reduced by as much as 30 per cent if all donor blood were tested for ALT and if donor units with elevated ALT levels were discarded. This prediction has not been tested in any clinical trial and is thus not well founded. Nevertheless, the implications of this propos al are the subject of intense discussion at this time. 3 " 6 It has been recognized that considerable additional information must be obtained and evaluated before a definitive decision on the implementation of ALT test ing can be made. This includes data on the distribu tion and implications of ALT levels in donors, infor mation on the epidemiologic link between donor ALT levels and hepatitis in recipients, an understanding of the legal ramifications of ALT testing, and a costbenefit analysis of a nationwide ALT testing program.
Costs were defined as the direct costs of testing and the indirect costs associated with loss of blood product, addi tional donor recruitment, and informing donors of their ab normal aminotransferase levels; costs ranged from $3,151 to $4,003 per 1000 units.
Our results suggest that if prospective studies dem onstrate that exclusion of blood with elevated amino transferase levels decreases non-A,non-B hepatitis in recipients, the net economic impact may be positive. However, because of major uncertainties about the medical consequences of non-A,non-B hepatitis, the ben efit estimates are so broad that they preclude a de finitive policy decision. (N Engl J Med. 1982; 307:1315-
21.)
Development of a cost-benefit analysis of imple mentation of ALT testing requires a model of the clini cal course of post-transfusion hepatitis. For this study, the foundations of such a model have been derived directly from the National Institutes of Health and the Transfusion-Transmitted Viruses studies. As yet, these foundations must be regarded as untested as sumptions, because the studies neither define the medical consequences of non-A,non-B infection nor prove that elimination of blood with high ALT levels would actually reduce the incidence of disease, 6 In brief, the potential benefits of donor testing are related to the estimate that over 10 per cent of all blood recipients have post-transfusion ALT elevations, of which over 90 per cent have been defined as indicative of non-A,non-B hepatitis and attributed to infectious agents transmitted by the blood.
1 Accordingly, Alter et al. have suggested that the 13.4 million units of blood and blood products transfused annually may be associ ated with nearly 300,000 cases of non-A,non-B hepati tis in the United States each year. 7 Medical expenses are incurred in treating some proportion of this dis ease, and losses in terms of productivity, pain, and suffering result. Even if the predictions of the Transfu sion-Transmitted Viruses and National Institutes of Health studies are valid, only a portion of these costs could be avoided by testing for ALT levels. When the results of these studies are used as a theoretical model, it is possible to conduct a preliminary quantitative analysis of the relative magnitudes of costs and bene fits of ALT testing and to determine the degree to which a commitment to ALT testing would save re sources by avoiding the mortality and morbidity asso ciated with non-A,non-B hepatitis.
These potential savings would be offset by the costs incurred in testing on a national basis as an interim measure, pending the development of specific serologic tests for carriers of the agent (or agents) of the infec tion. Every unit of blood would have to be analyzed after collection, because current technology does not THE NEW ENGLAND JOURNAL OP MEDICINE Nov -18, 1982 *\ permit convenient screening of faiood donors for ALT levels. In ad dition, elimination of blood with high ALT levels would result in a loss of 1,5 to 3 per cent of the nation al blood supply, representing the proportion of healthy donors with abnormal ALT levels. Additional costs would thus be incurred in re cruiting donors and drawing re placement blood to maintain ade quate supply levels and avoid shortages. Furthermore, discarding blood that had already been collect ed and processed would result in wasted processing costs. Finally, ethical requirements dictate that donors with markedly elevated ALT levels be informed of this find ing, leading to additional costs, al though with a potential for some benefit to the donor with respect to early detection of disease.
We have carried out a cost-bene fit analysis of ALT testing, in which the following questions were ad dressed: Are the costs required to conduct ALT testingjustified in the light of the anticipated benefits re sulting from testing? Is there a cutofT level of ALT, below which rejec tion of donor blood is not justified on the basis of economic criteria alone? What are the comparative economic implications of the results of the Transfusion-Transmitted Vi ruses and National Institutes of Health studies? Answers to these questions would be useful in trans lating current information into an economic context that would aid policy formulation, in the event that the assumptions employed in this study are validated by appropriate investigations. 
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METHODS
Analytical Approach
In (his report the costs and benefits relating to the implementation of testing ALT levels of all blood donations are defined. Both costs and benefits are valued in purely monetary terms and are assigned to society at large, 8 In other words, the analysis ignores the fact that although the benefits are distributed among the blood recipients, the costs are incurred by blood-collection centers.
Both costs and benefits are expressed in terms of 1000 blood units distributed and transfused. The-analysis focuses on the donors and potential recipients associated with these 1000 units. The organiza tional model is a typical blood-collection center in a large, not-forprofit community agency. The center's costs include the incremental expenditures of applying ALT testing plus the resources used by donors who seek further medical evaluation because of abnormal ALT levels.
Benefits are calculated in terms of social costs of resources that would be used by blood recipients whose post-transfusion non-A, tion-B hepatitis would have been avoided by ALT testing. This model was developed from the two studies cited earlier on the rela- tion between donor ALT levels and the post-transfusion mfecfiopj/jj.
We assume that if implemented, ALT testing would wnwjjf.: indefinitely. Therefore, if it is economically beneficial to test 1000 units, then benefits will accrue with transfusion of each quent 1000 units. All costs are considered as incurred in the curtW; period and are therefore not discounted. Benefits, on the other Mfl , -. must be classified according to the time of their occurrence--t.® present and the future. Those accruing in future year must be discounted in order to be added to current benefits and to V; * pared with current costs. Cost-benefit analysis derives an of the overall net benefits -i.e., the excess (or shortfall) 0 ' in relation to costs -so that the economic desirability ofa prog can be determined.
,,
Cost of Testing Figure I shows a flow chart for ALT testing in the .' , center used for this study. In order to develop cost < s ''' ' J ' ( following assumptions have been made; (J) testing w . )ftj formed, and blood with levels of ALT higher than a pndt cutoff point will be discarded; (2) deferred; and (5) some donors with high ALT levels will seek medi cal advice and evaluation. Each of these assumptions represents some incurred cost. The basic cost of each element is defined in Table 1 ; most of these elements are self-explanatory. The direct cost of testing includes expenditures for reagents, supplies, equipment, training, and main tenance and is derived on the basis of consultations with a number of manufacturers of appropriate equipment and reagents. Direct costs also include staff time, with one additional staff member required for each blood center and additional costs lor record keeping and profi ciency. All these costs are incurred in the current period and are not discounted. The blood center is assumed to be operating in the range of constant returns to scale, so that all costs are kept at a minimum.
The cost element associated with the rejection of collected blood represents the resources expended to collect that blood unit. This figure was derived from the weighted mean average processing fee of all whole blood and blood components distributed by the Red Cross in the fiscal year ending June 30, 1980. Costs associated with re placing discarded blood include incremental costs of recruiting new donors and costs of testing replacement blood. It should be noted that a proportion of this replacement blood would itself prove un acceptable and be rejected, leading to another round of recruitment and testing (Fig, 1) . This "second-cycle effect" is assumed to occur within the current time period.
Finally, most donors are anxious to be informed about any abnor malities in their test results, as shown by responses to a question naire administered to donors during a study of donor ALT levels, 9 Fifty per cent of donors thus informed seek further medical evalua tion and advice. At a minimum, the physician is obligated to repeat the ALT test and, moreover, is likely to seek additional diagnostic criteria, A follow-up office visit will also be necessary, A number of other potentially relevant factors have not been "incorporated into the cost estimates presented here. First of all, the increased difficulty of donor recruitment, caused by the rise in donor rejection rates, may raise the cost of ALT testing. Secondly, long-term attrition of donors will occur if donations are to be de ferred on the basis of an elevated ALT level. The apparently chronic nature of non-A,non-B hepatitis, the variability of ALT levels among infected patients, and the duration of the carrier state 10 all suggest that lifelong deferral may be appropriate. Finally, problems in standardization of methods imply major difficulty in efficient administration of the program.
On the other hand, the overall cost of testing could be reduced by the development of an Inexpensive procedure for identifying donors with high ALT levels before phlebotomy. Figure 2 shows the natural history of post-transfusion non-A, "on-B hepatitis, for the purpose of estimating the potential use of resources. Each branch point shows an estimate of the proportion of rases, based on published information on clinical follow-up of pa tents with chronic transfusion-associated non-A,non-B hepati tis 11 ' 12 and on the opinions of a number of gastroenterologists and t'intcians familiar with chronic forms ofhepatitis. Outcomes consid ered likely to result in use of resources or loss of earnings are high- This outcome has been defined as acute, symptomatic hepatitis. Characteristically, this disease is self-limiting, but some patients may die. Regardless of the appearance of acute symptoms, it is accepted that some 50 per cent of all cases of post-transfusion ALT elevations will continue for more than six months and thus be classified as chronic, 1 ' 2 Between 10 and 30 per cent of such eases of chronic infection have been estimated to lead to cirrhosis,"" 12 8 to 50 per cent of which may be symptomatic, eventually leading to death in most cases (95 per cent). Finally, it is estimated that some 25 per cent of chronic infections that do not result in cirrhosis will lead to symptomatic disease.
Benefits of Testing
Natural History
We have sought to validate at least some of the estimates in this model of hepatitis by developing an independent estimate of the number of deaths from cirrhosis that are attributable to transfusionassociated non-A,non-B hepatitis. Approximately 31,500 such deaths are reported annually in the United States," Twenty to 40 per cent (6300 to 12,600) have causes other than alcoholism, A very conservative breakdown of these deaths not associated with alcohol ism suggests that nearly 50 per cent (3150 to 6300) are related to toxic chemicals, drug abuse, hepatitis B, and other pathogenic agents. This leaves an excess of 50 per cent of deaths from nonalco holic cirrhosis that can be attributed to non-A,non-B hepatitis. This hepatitis can be of the sporadic type or the post-transfusion type. In a recent study, only about 12 per cent of patients hospitalized with non-A,non-B hepatitis had transfusion-related disease, 14 but trans fusion-related hepatitis is more likely to develop into chronic illness than is sporadic hepatitis. Specifically, Norkrans et al, reported that only 7,1 per cent of their patients with non-A,non-B hepatitis had chronic transaminase elevations, but the majority of their cases were not transfusion-related, 15 The rate of progression to chronic disease is much lower than the figure of 50 per cent in patients with post transfusion hepatitis (Fig. 2) , If it is assumed that 85 per cent of THE NEW ENGLAND JOURNAL OF MEDICINE Nov, •8, 1982 | §I.
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non-A,non-B hepatitis is sporadic and 15 per cent is transfusionrelated, and that 7.5 per cent of cases of the sporadic disease and 50 per cent of the transfusion-related disease become chronic, then it can be calculated that 46 per cent of the chronic cases are sporadic and 54 per cent are transfusion-related. If 31,500 deaths due to cirrhosis occur per year, the range of deaths due to non-A,non-B post-transfusion hepatitis is 1700 to 3400 per year. This range is compatible with the lower end of the range of 1140 to 21,375 deaths derived from the estimates presented in Figure 2 and Table 4 and from Alter's suggestion that there may be more than 300,000 cases of post-transfusion non-A,non-B hepatitis each year in the United States.
7
Other factors suggest that the actual severity of non-A,non-B hepatitis may tend to lie at the low end of the range of estimates. For example, the actual incidence of post-transfusion hepatitis reported to voluntary blood-collection agencies is on the order of 0,1 to 0.2 cases per thousand units issued (Dodd RY; unpublished data). Fur thermore, although neither the Transfusion-Transmitted Viruses Study nor the National Institutes of Health study specifies the pro portion of infected recipients with clinically or economically serious disease, biopsy-proved asymptomatic chronic post-transfusion liver disease apparently tends to resolve rather than to become exacer bated. 12 
Medical Care, Work Loss, and Death
Each of the three symptomatic end points -acute hepatitis, cir rhosis, or chronic hepatitis -will itself take a variable proportion of financial resources. These resources are summarized in Table 2 .
The cost of a single office visit to a physician has been derived by adjusting the 1977 price of $23, obtained from the National Medical Care Expenditure Survey, 16 for inflation in physician fees over the period 1977 to 1980 (30.7 per cent). 17 The cost of a test for blood chemistry has been derived from the schedule of Medicare charges of 12 chemistry tests for 1980 for major metropolitan areas. 18 The per diem cost of a hospital stay is assumed to be $256 -the national average expense per day for non-federal short-term general hospi tals, 17 A figure for lost wages was derived from the mean national wage in private, nonagricuttural jobs. 17 The economic cost of death is considered as the loss of productivity due to premature shortening of expected work life, valued as the remaining expected lifetime earnings discounted to the current time period. As discussed by Cooper and Rice, 19 this approach is the most commonly used formal method of valuing human life. Death from acute non-A,non-B hepa titis is assumed to occur at an average age of 57,5 years -a figure based on the average age of patients given transfusions who are discharged alive from the hospital (Hornbrook MC: unpublished data). It is difficult to estimate the age distribution of patients dying of cirrhosis, because of a lack of adequate follow-up information. Therefore, such deaths are assumed to occur over the age rangeofSS to 69, to be distributed evenly over the 15-year post-transfusion period, and to occur in the hospital. The average value of discounted expected remaining lifetime earnings for this age group, adjusted for the sex distribution of recipients, is $47,323 on the basis of the above data,"' 19 '*' Several factors related to the potential benefits of ALT testing have been omitted in deriving the above estimates. First of all, improvements in donor health may result from detection of abnor mal liver function. However, biopsy studies of donors with chronic ALT elevations do not suggest any clinically important disease (Sainpliner RE: personal communication). The major benefits are therefore assumed to be the reassurance and counseling provided by the physician, which cannot be quantified. Moreover, many factors other than disease, such as age, sex, ethnic origin, and life style, affect the distribution of donor ALT levels. It is thus difficult to assess the relevance of a large-scale screening program of liver func tion to the health status of the donor population. Secondly, the pain and suffering of the recipient who contracts any of the various clini cal forms of non-A,non-B hepatitis have not been assigned a value. Psychological factors are exceedingly difficult to evaluate without objective assessment, such as willingness to pay for medical care.
Offset ting the above underrepresentation of benefits are two im portant considerations: use of a wholly voluntary blood supply will decrease the benefits of ALT testing'" 2 ; and patients In both the Transfusion-Transmitted Viruses Study and National Institutes of •See text foe derivation of estimates. ; v.
Health Study were specifically selected so that their survival and underlying good health allowed the identification of even the mildest form of postoperative liver dysfunction. Indeed, almost 3 per cent of patients not given transfusions had similar signs.' Therefore, blood recipients may not be properly represented in this respect by the National Institutes ofHealth and Transfusion-Transmitted Viruses studies. Many patients requiring transfusion die of their underlying disease-a factor included in the calculations -but many also have disorders that are likely to be of much greater concern, or indeed economic consequence, than the hepatitis that may accom pany that disease. Finally, it has been assumed throughout that screening of donors; for ALT will have the same relative effect on each outcome of: non-A,non-B infection. Although there is no published evidence to , the contrary, it should be recognized that elevated donor AL'I lewis may be selectively associated with only one of the potential end points. Thus, if donor ALT elevations are more often associated with cirrhosis in the recipient, then the benefits of testing are increased. Conversely, no tangible benefits would accrue if ALT testing affect-. ed only the incidence of asymptomatic or resolving disease.
Frequency of Elevated ALT and Non-A.Non-B Hepatitis
The costs and benefits derived from the above information have been applied to data from the two studies cited 1,3 (TabteS^'TK proportion of blood units with elevations in ALT is defined accord ing to the respective criteria in the two studies. Two st^'.tr.m !-sfl> used in the Transfusion-Transmitted Viruses Study {45 •!. I w per liter) are analyzed. In order to estimate the amoi'i.r u detected through ALT testing, the infection rate per 1000 blood units with subthreshold ALT levels is subtracted from !n j i.v:r~l infection rate per 1000 blood units. iBased on experience in informing donors about ALT levels, during a Red Cross research study,
RESULTS
Cost ol Testing
The costs incurred in providing 1000 units of blood with ALT levels that are below the assigned cutoff point are defined in Table 4 . No matter what percent age of donors are rejected on the basis of ALT eleva tions, the primary costs of testing each unit remain the same. However, the percentage of blood rejected clear ly affects overall loss of blood-center revenue from dis carded blood units, marginal recruitment costs, and all second-cycle effects. It may also affect donor notifica tion and follow-up costs, although we have assumed that only donors with an ALT level greater than 60IU per liter would be informed, on the basis of criteria developed from the Transfusion-Transmitted Viruses Study, whereas all donors with elevated ALT would be informed if the cutoff were defined according to Alter's criteria. 2 The percentage of donors informed would thus be 1.6 per cent in both cases.
The overall costs incurred per 1000 blood units range from $3,151 to $4,003, depending on the donor rejection rate.
Benefits from Testing
The potential benefits of ALT testing cannot be cal culated with any degree of precision since both the proportion of cases leading to a specific outcome (Fig.  2) and the resource costs within that outcome (Table  2 ) must be estimated. When Figure 2 is used as a composite model representing the mean of all costs of non-A,non-B post-transfusion hepatitis, the upper and lower limits of expenditures associated with each case of post-transfusion ALT elevation are defined (Table  5 ). In order to arrive at the resource costs within each outcome, the following estimates have been made. Among the 25 per cent of patients in whom acute, symptomatic hepatitis develops, 1 " 2 10 to 25 per cent 21 will lose eight weeks of work 2 and will be hospitalized for an average of 11.45 days, the national figure for post-tranfusion hepatitis (Code 999.2 in the Interna tional Classification of Diseases Adapted [ICDA] 23 ), representing a cost of $5,201. Of these patients 1 to 7.2 per cent 24 will die in the hospital at a total resource cost of $91,121 per death (present value). Each of the nonhospitalized patients is assumed to make at least two office visits to a physician and to undergo appro priate blood-chemistry testing, at an estimated total cost of $90. These events are assumed to occur within a year of transfusion, and thus the resource costs are not discounted.
Among the 5 to 15 per cent of all patients with an end point of cirrhosis, it is estimated that between 8 and 50 per cent will have symptoms requiring 9.6 days of hospitalization (ICDA 571.9, unspecified cirrhosis without alcoholism 23 ) and 10 physician visits in the hospital, plus eight weeks' loss of earnings, represent ing a cost of $4,638. The vast majority (95 per cent) of these patients will die in the hospital, resulting in the loss of their remaining lifetime earnings. These deaths are assumed to occur over a 15-year period and to involve $49,440 in discounted hospital and physician expenses, as well as the loss of remaining lifetime earnings.
Some 35 5 per cent will need hospitalization for further tests or support, incurring the same cost as a short-term hospi talization. This hospitalization is assumed to occur within a year of transfusion and is not discounted.
The lower limit of economic costs for the average case is thus obtained by summing the lower estimates for each variable, giving a figure of $364. Similarly, use of all high estimates gives an upper limit of $4,328. The use of mid-range estimates gives a value of $2,346. In order to define the economic benefits of the program, this range of estimates can be applied to the number of cases of non-A,non-B post-transfusion hepatitis that would be expected to be prevented by exclusion of donor blood with high ALT levels.
The above discussion of the economic impact of non-A,non-B post-transfusion hepatitis assumes that all other factors are held constant -that is, the only change in the patient's status is the occurrence of the hepatitis. How ever, most persons who require a blood transfusion are likely to have other clinical manifestations and outcomes much more severe than non-A,non-B hepatitis. Again, it is not possible to assess these "mask ing" effects because of the lack of long-term follow-up data on pa tients with non-A,non-B hepatitis. It is estimated that 10 per cent of all transfusion recipients die during their hospital stay (Hornbrook MG: unpublished data); in these cases, the advantages of the ALT testing program cannot be observed. Therefore, in this analysis the esti mated costs of non-A,non-B hepati tis have been reduced by 10 per cent overall.
The benefits of ALT testing, ex pressed in terms of 1000 blood units, are obtained by multiplying the number of avoidable cases by costs and adjusting downward by 10 per cent. As shown in Table 6 , these benefits cover a range of $898 to $10,673, on the basis of data from the National Institutes of Health study, 2 and $1,733 to $20,606 or $2,660 to $31,629, on the basis of the T ransfusion-Transmitted Viruses Study 1 and a respective cutoff point of 60 or 45 IU per liter. The net benefits (i.e., the difference between total-benefits and total costs) of the ALT testing program per 1000 blood units range from -$2,253 to $7,522 for the National Insti tutes of Health data, with a mid-range estimate of $2 ,634. According to the data from the TransfusionTransmitted Viruses Study, the net benefits range from -$1,418 to $17,455, or -$1,343 to $27,626, for the respective cutoff ALT levels of 60 and 45 IU per liter. The mid-range net benefit estimates are $8,018 and $13,142 per 1000 blood units. Clearly, positive net benefits reveal that the decision to undertake the ALT testing program would return more in benefits to soci-£ ety than the costs required to implement the program whereas negative net benefits indicate the converse.
DISCUSSION
Although the costs of ALT testing can be defined with a reasonable degree of certainty, it is obvious thai the corresponding benefit estimates are imprecise. The major cause of the wide margin of benefit estimates is the inability to develop an accurate model of the natural history and resource costs associated with non-A,non-B hepatitis. This analysis identifies cirrho sis with resulting deaths, along with acute hospitaliza tion with or without death, as the outcomes accounting for maximum use of resources. It is no surprise to find that these sequelae of non-A,non-B infection are also the most important areas of clinical and ethical con cern. However, neither the incidence noi die severity of these forms of disease can be accurately definewithout prospective studies of large populations o transfusion recipients.
The finding that reducing deaths is likely to.accoun^ for 60 to 90 per cent of benefits horn ALT-tcs""i> (Table 5) suggests that the results may be sensitive the economic value assigned to piemature deat: i. value could be underestimated by at least hal > tends to occur earlier in the peak earning ° , blood recipient, 19 if deaths tend to be « among high-income persons (e.g., male rccl,, V t } lC or if the value of life is deemed to be higher < _ earned income of the recipient, 1 hus, . . v t j iC n suiting from post-transfusion hepatitis is j^jy doubling the value assigned to p re ma t u re c e»
• jf doubles the expected benefits from ALJ •rtaiitv is tow, halving the value of premature death the expected benefits by less than a third. By ' "mparison, a 10-fold difference in the expected bene--fits ftoin ALT testing may be attributed to the range of ' mortality estimates. This demonstrates that the results of this cost-benefit analysis are more affected by vari ation in estimates of mortality from non-A,iion-B h C p a iias than by variation in the economic values as signed to each potential outcome, ~' ' CONCLUSIONS /•At this point it is reasonable to ask whether this analysis piovides sufficient information to justify a policy decision on the nationwide implementation ofa donor-AI.T testing program costing an estimated ' $4-2,2 million, According to the models and mid-range estimates developed above, ALT testing would be highly beneficial overall. Moreover, if the criteria of . the Transfusion-Transmitted Viruses Study are ac cepted, use of a cutoff of 45 IU per liter is more advan tageous than use of 60 IU per liter. However, midrange estimates are applicable only if the uncertainty ; of each estimate is symmetric about the midpoint, but as shown, independent evidence tends to favor the Sower end of the range of estimates. Nevertheless, if the 'actual resource cost associated with post-transfusion non-A,non-B hepatitis does lie above the extreme low end of the range of estimates, then ALT testing in blood donors would be justified on economic grounds.
The most important conclusion of this study is that current information about the frequency and severity of clinically apparent post-transfusion non-A,non-B hepatitis is not sufficient to provide the precision in estimating the benefits of ALT testing required for policy decisions. It must be recognized that no mean ingful data are available to define the true incidence and severity of clinically important post-transfusion hepatitis or its sequelae. Furthermore -and even more important -no randomized prospective study has shown that exclusion of blood from donors with elevated ALT levels lowers the incidence of either symptomatic or asymptomatic post-transfusion viral hepatitis, 6 In the absence of this validation, there is no way of establishing the appropriateness of the clinical model used in this analysis. Since this study shows that major economic benefits may be derived from preven tion of non-A,non-B infection at reasonable cost, fur ther research on this issue should be pursued without delay.
On the other hand, consideration must also be given to additional or alternative approaches to the reduc tion of transfusion-associated disease. More effective and judicious use of blood, the use of autotransfusion procedures, more effective inventory controls, and an even stronger commitment to an all-volunteer, com munity-oriented blood-collection system should all be evaluated. The Transfusion-Transmitted Viruses Study presented a rationale for testing hepatitis B core antibody that appears as reasonable as that for ALT testing; perhaps this approach also merits consider ation. 25 In fact, the uncertainties associated with al! these issues illustrate the difficulties of accepting an interim solution to post-transfusion non-A,non-B hepatitis and demonstrate a compelling need for a spe cific test to identify the carriers of this disease.
